Antipsychotic-Induced Movement Disorders and Metabolic Effects

Antipsychotic drugs cause two broad families of adverse effect that shape how they are chosen and tolerated: movement disorders linked to dopamine blockade in motor pathways, and metabolic effects such as weight gain and dyslipidaemia associated especially with several second-generation agents. Together these define much of the tolerability burden of the class.

Definition

Antipsychotic-induced adverse effects comprise the drug-related movement disorders arising from dopamine D2 blockade in motor pathways and the metabolic disturbances, such as weight gain and dyslipidaemia, associated with the antipsychotic class.

Scope

This topic covers the principal adverse effects of antipsychotics: the extrapyramidal movement disorders (including acute reactions and tardive dyskinesia) tied to nigrostriatal D2 blockade, and the metabolic effects that dominate the burden of many atypical agents. It is a reference description of mechanism and comparative risk and does not give monitoring, dosing, or treatment instructions.

Core questions

• Why does dopamine D2 blockade produce movement disorders?
• How do acute extrapyramidal symptoms differ from tardive dyskinesia?
• Which agents carry the greater metabolic burden, and why?
• How do the movement and metabolic profiles trade off across the two generations?

Key concepts

• Extrapyramidal symptoms (acute dystonia, parkinsonism, akathisia)
• Tardive dyskinesia
• Weight gain and dyslipidaemia
• Hyperglycaemia and diabetes risk
• Generation-related differences in side-effect burden

Key theories

Nigrostriatal D2 blockade and motor effects

Because antipsychotic D2 antagonism is not confined to mesolimbic pathways, blockade in the nigrostriatal pathway disrupts motor control, producing the spectrum of extrapyramidal effects; the relationship between D2 affinity and clinical potency helps explain why high-potency agents carry greater motor liability.

Mechanisms

Movement disorders arise mainly from dopamine D2 blockade in the nigrostriatal pathway. Acute effects include dystonia, drug-induced parkinsonism, and akathisia, while tardive dyskinesia is a later, sometimes persistent movement disorder. Seeman's affinity-potency relationship helps explain why potent D2 antagonists tend to carry higher extrapyramidal liability. Metabolic effects are a separate axis: several agents, through histaminergic and other actions affecting appetite and metabolism, promote weight gain, dyslipidaemia, and disturbed glucose regulation, and this burden falls disproportionately on certain second-generation drugs.

Clinical relevance

The adverse-effect profile is a central consideration in how antipsychotics are evaluated, because tolerability and long-term physical-health risk influence the overall benefit of treatment. Movement and metabolic effects often pull in opposite directions across agents. This entry describes mechanisms and comparative risk for reference and is not a guide to monitoring, prescribing, or individual treatment decisions.

Epidemiology

Systematic review of one-year studies reports a lower incidence of tardive dyskinesia with second-generation than first-generation antipsychotics, while reviews of physical-health risk document substantial metabolic burden with several second-generation agents, contributing to the elevated rates of cardiometabolic disease observed in people with serious mental illness.

Evidence & guidelines

Comparative meta-analyses rank antipsychotics along dimensions of weight gain, extrapyramidal effects, and other adverse outcomes, and reviews of physical-disease risk synthesise the metabolic evidence. These syntheses underpin guideline emphasis on balancing efficacy against tolerability when the class is considered.

History

Extrapyramidal effects were recognised soon after the introduction of the first antipsychotics and gave the older drugs their 'neuroleptic' character, with tardive dyskinesia emerging as a feared long-term complication. As second-generation agents reduced motor liability, attention shifted in the 1990s and 2000s to their metabolic effects, reframing antipsychotic safety around cardiometabolic as well as movement outcomes.

Debates

How should movement-effect and metabolic risks be weighed against each other?

Because typical agents tend toward movement disorders and many atypicals toward metabolic effects, comparative meta-analyses show no single drug minimises all harms, and how to weigh extrapyramidal versus cardiometabolic risk remains a matter of judgement.

Key figures

• Christoph Correll
• Stefan Leucht
• John Kane
• Philip Seeman

Seminal works

• correll-2004-td
• correll-2015

Frequently asked questions

Why do antipsychotics cause movement problems?

Their dopamine D2 blockade extends to the nigrostriatal motor pathway, disrupting movement control and producing extrapyramidal effects such as parkinsonism, dystonia, akathisia, and, over time, tardive dyskinesia.

Do newer antipsychotics avoid side effects?

Not entirely. Second-generation agents generally carry a lower risk of movement disorders such as tardive dyskinesia but several add a substantial metabolic burden, so the side-effect problem shifts rather than disappears.